At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,741 enrolled
Drug / intervention
Apixaban +3 moredrug
Likely dose
Apixaban 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.
In Brief
A Phase 2 clinical trial evaluating Apixaban and Placebo for Acute Coronary Syndrome (ACS). Completed, enrolled 1,741 participants across 151 sites in 14 countries.
Detailed Summary
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome (ACS)
CountriesAustria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Poland, Russia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartMay 2006
Primary CompletionMay 2008
TodayJul 2026
First PostedApr 12, 2006
Enrollment StartMay 1, 2006
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.2 years ago
Interventions
Apixabandrug
Tablets, Oral, 2.5 mg, twice daily, 26 weeks
Apixabandrug
Tablets, Oral, 10 mg, once daily, 26 weeks
Placebodrug
Tablets, Oral, 0, twice daily, 26 weeks
Apixabandrug
Tablets, Oral 10 mg, twice daily, 26 weeks